STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #384 by analyst upside · 2026-09-09
IMUX
Immunic, Inc.
Healthcare · Market Cap $174M · P/E 0x
ANALYST PRICE TARGET
+238.2%
implied upside to consensus target
Current Price $12.74
Consensus Target $43.09
Bull Target $85.0
Bear Target $22.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
11
Hold
0
Sell
0
52-Week Low $5.06
52-Week High $17.43
YTD Return +118.5%
FUNDAMENTALS
Market Cap $174M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.55
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $5.06
52-Week High $17.43
Current Price $12.74
Bear Target $22.0
Bull Target $85.0
● Now $12.74 ● Target $43.09
TRADING DATA
Avg Volume 197K
YTD Return +118.5%
Analyst Count 11
Consensus Buy
Upside to Target +238.2%
Last Updated 2026-09-09

ANALYST SUMMARY

Immunic, Inc. (IMUX) is currently trading at $12.74 with a Wall Street consensus price target of $43.09, implying potential upside of 238.2% over the next 12 months. 11 analysts currently cover IMUX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $85.0, while the most cautious has a target of $22.0.

IMUX operates in the Healthcare sector with a market capitalisation of $174M. The stock is up 118.5% year-to-date and is currently trading near the upper end of its 52-week range of $5.06 – $17.43.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IMUX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush ● Initiated
Outperform 2026-08-17 Building track record
B. Riley Securities - Reiterated
Buy → Buy 2026-05-22 17% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-04-30 31% win rate (48 calls)
Stifel ● Initiated
Buy 2026-04-17 Building track record
D. Boral Capital ↓ Downgrade
Buy → Hold 2026-04-15 32% win rate (25 calls)
Guggenheim ● Initiated
Buy 2026-03-24 62% win rate (8 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-02 31% win rate (48 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-02-13 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →